Skip to content

Summit Therapeutics SMMT Investment Purchases

Investment Purchases at other companies

Merck & Co. logo
Merck & Co.MRK
$374M-37.1%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$500M+13.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$144M-42.6%
Gilead Sciences logo
Gilead SciencesGILD
$525M
Biogen logo
BiogenBIIB
$748.8M
Eli Lilly logo
Eli LillyLLY
$297M+50.8%

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's investment purchases?
Summit Therapeutics (SMMT) reported investment purchases of $177.29M in Q1 2026.
What does investment purchases mean?
Cash spent to purchase short-term investments or marketable securities.
How do you interpret investment purchases?
High levels of purchases suggest the company has excess cash to deploy, while low levels may indicate a need to preserve cash for operations.
How does investment purchases compare across companies?
Standard for companies with large cash reserves; reflects the conservative nature of the company's treasury policy.